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Which patients with suspected 
exposure to pertussis should 
receive prophylaxis?
Evidence-based answer
Clinical commentary
only	high-risk	close	contacts	of	known	
cases	should	receive	prophylactic	
antibiotics,	according	to	the	Centers	for	
Disease	Control	and	Prevention	(CDC).	The	
CDC	defines	high-risk	as	(1)	infants	who	are	
<12	months,	(2)	those	especially	vulnerable	
to	the	complications	of	pertussis,	or	(3)	
those,	such	as	health	care	workers,	in	
close	contact	with	high-risk	individuals	
(strength	of	recommendation	[sor]:	C,	
based	on	consensus/expert	opinion).	
evidence	is	insufficient	to	support	a	benefit	
of	prophylactic	antibiotic	treatment	for	all	
household	pertussis	contacts	to	prevent	the	
development	or	spread	of	illness	(sor:	B,	
based	on	a	systematic	review	of	studies).
Give special attention to high-risk 
close contacts, especially infants
recently,	in	the	medical	college	where	I	
teach,	a	student	came	down	with	pertussis.	
several	weeks	after	the	onset	of	symptoms,	
she	was	diagnosed	and	determined	to	be	
no	longer	contagious.	When	she	coughed	
in	class,	however,	I	worried	that	she	could	
have	infected	us	all.	No	one	received	
prophylactic	antibiotics.	To	date,	I	do	not	
know	of	anyone	who	was	in	close	contact	
with	this	student	who	has	come	down	with	
the	illness.	However,	direct	special	attention	
to	high-risk	close	contacts,	especially	
infants,	as	they	can	have	devastating	
results	from	infection.
Jose Rodriguez, MD
Florida	state	university	College	of	medicine,	
Tallahassee
z Evidence summary
A Cochrane review1 of antibiotic use for 
pertussis prophylaxis, including stud-
ies published through 2002, found only 
2 randomized, well-controlled trials 
(RCTs) that compared attack rates be-
tween contacts receiving placebo or anti-
biotic therapy. Neither trial included in-
fants under age 6 months. The reviewers 
concluded that evidence was insufficient 
to determine a treatment benefit. The 
larger study2 included 310 household or 
family contacts, randomized by house-
hold to 10 days of erythromycin estolate 
or placebo. Positive cultures or clinical 
pertussis developed in 4.8% of treated 
contacts and 6.1% of controls (relative 
risk [RR]=0.8; 95% confidence interval 
[CI], 0.3–2.2). Adverse side effects oc-
curred in 34% of the erythromycin group 
and 16% of controls (RR=2.2; 95% CI, 
1.4–3.3; number needed to harm=5.6).
Focus on those at high risk
Despite the paucity of RCTs, the CDC 
and other public health agency guide-
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lines recommend postexposure prophy-
laxis for certain close contacts to protect 
high-risk individuals, defined as those 
who could develop severe disease or 
experience adverse outcomes if pertussis 
developed.3–6
High-risk individuals include:
• Infants <1 year old
•  Pregnant women in their third 
trimester
• the immunocompromised
•  those with underlying medical condi-
tion such as chronic lung disease, respi-
ratory insufficiency, or cystic fibrosis
•  those who have close contact with 
any of the above high-risk individuals 
(eg, household members or health-care 
workers providing face-to-face care).
Close contact is defined as: 
•  confinement in a closed space for 
>1 hour with a known case, or
•  direct contact with respiratory, oral, or 
nasal secretions from a symptomatic 
person, or
•  face-to-face exposure within 3 feet of a 
symptomatic patient.
Clinical trials involving such patients 
have not been conducted.6,7 Maintenance 
of active vaccination status is an effective 
means to prevent the spread of pertussis 
among the general population and has 
been suggested as a means to control lo-
cal outbreaks,6 though it has no role in 
immediate postexposure prophylaxis for 
an individual. In one RCT, no (0/60) fully 
immunized child in a household with per-
tussis developed whooping cough, with or 
without antibiotic prophylaxis. Among 
unimmunized children, pertussis devel-
oped in 4/20 receiving erythromycin pro-
phylaxis and 2/11 receiving placebo.8
Macrolides (erythromycin, clar-
ithromycin, or azithromycin) are recom-
mended for postexposure prophylaxis. 
Trimethoprim-sulfamethoxazole is a sec-
ond-line agent.5 A short course of erythro-
mycin (7 days), azithromycin (3–5 days), 
or clarithromycin (7 days) is as effective 
as a 2-week course of erythromycin in 
eradicating Bordetella pertussis from the 
nasopharynx.9 
Recommendations from others
Recommendations from others are in the 
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Recommendations for pertussis prophylaxis
orGanizaTion rECommEndaTion
Canadian guidelines4	 reserve	prophylaxis	for		
	 •	 vulnerable	(high-risk)	contacts	
	 •	 Those	who	care	for	vulnerable	individuals	
	 Prophylaxis	must	be	started	within	21	days		
	 of	exposure
Public health Seattle  Prophylax	only	high-risk	individuals	with	
and King County5	 •	 Prolonged	(>1	hour)	exposure	to	catarrhal		
	 	 stage	disease	
	 •	 Contact	within	3	feet	
	 •	 Direct	contact	with	secretions	(ie,	kissing)
CdC6	 During	institutional	outbreaks	
	 •	 Treat	early	in	symptomatic	course	
	 •	 Prophylax	only	those	at	high	risk	
	 •	 Warn	healthy	contacts	to	report	new		
	 	 symptoms
Maintenance of 
active vaccination 
status is an  
effective way to 
prevent pertussis 
spread among the 
general population
